Description
Latin name
Lamisil
packaging 14 pcs
Indications
onychomycosis caused by fungi dermatophytes
mycoses of the scalp
fungal infections of the skin – treatment of dermatomycoses of the trunk, legs, feet, as well as yeast infections of the skin caused by fungi of the genus Candida (for example, Candida albicans, loca, in those cases the severity or prevalence of infection determines the feasibility of oral therapy.
Note: unlike Lamisil ® topical preparation, Lamisil ® for oral administration is not effective for multi-colored lichen.
Contraindications
Hypersensitivity to terbinafine or to any other ingredient in the drug.
Composition
1 tablet contains:
Active ingredient: terbinafine (in the form of hydrochloride) 250 mg
Excipients: magnesium stearate silicon dioxide hydrochloride colloidal sulphate .
Side effects
From the hematopoietic system: very rarely – neutropenia, agranulocytosis, pancytopenia. In very rare cases, the use of the drug showed the development of qualitative or quantitative changes in the form of blood elements (neutropenia, agranulocytosis, thrombocytopenia, pancytopenia). In the case of the development of qualitative or quantitative changes on the part of blood cells, the cause of the disorders should be established and the issue of reducing the dose of the drug or, if necessary, discontinuing therapy with Lamisil ®, should be considered.
On the part of the immune system: very rarely – anaphylactoid reactions (including angioedema), cutaneous and systemic lupus erythematosus.
On the part of the nervous system: often – headache sometimes – disturbances in taste sensations, including their loss (usually recovery occurs within a few weeks after stopping treatment) very rarely – dizziness, paresthesia, hypesthesia. There are separate reports of cases of prolonged violations of taste sensations. In some cases, while taking the drug, there was a decrease in food intake, which led to a significant reduction in weight.
From the hepatobiliary system: rarely – hepatobiliary dysfunction (predominantly cholestatic in nature), including very rare cases of severe liver failure (some fatal or requiring liver transplantation). In most cases, when liver failure developed, patients had serious concomitant systemic diseases and the causal relationship of liver failure with Lamisil ® was doubtful.
From the digestive system: very often – a feeling of fullness of the stomach, loss of appetite, dyspepsia, nausea, mild abdominal pain, diarrhea.
From the skin and subcutaneous tissue: very often – mild skin reactions (rash, urticaria) very rarely – serious skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis) psoriasis-like rashes on the skin or exacerbation of psoriasis. Cases of hair loss have been very rare, although a causal relationship with this drug has not been established. When, if progressive skin rash develops, treatment should be discontinued.
From the side of the musculoskeletal system: very often – arthralgia, myalgia.
Others: very rarely – feeling tired.
Drug interactions
Effect of other drugs on terbinafine. Terbinafine plasma Cl can be accelerated under the influence of drugs – metabolic inducers, and suppressed under the influence of cytochrome P450 inhibitors. If necessary, the simultaneous use of the above drugs and the drug Lamisil ® may require appropriate correction of the dosage regimen of the latter.
Cimetidine may enhance the action of terbinafine or increase its concentration in plasma. Cimetidine reduces Cl terbinafine by 33%.
Rifampicin may weaken the action of terbinafine or decrease its concentration in plasma. Rifampicin increases Terbinafine Cl by 100%.
Effect of terbinafine on other drugs. In vitro studies and in healthy volunteers show that terbinafine has little potential to suppress or enhance Cl of most drugs that are metabolized by the P450 cytochrome system (e.g. terfenadine, triazolam, tolbutamide, or oral contraceptives), except that are metabolized by CYP2D6.
Terbinafine does not affect Cl antipyrine or digoxin.
There have been reports of several cases of menstrual irregularities in patients taking Lamisil ® in conjunction with oral contraceptives, although the frequency of these disorders does not exceed the average frequency of such disorders in patients taking only oral contraceptives.
Terbinafine may enhance the action of caffeine or increase its concentration in plasma. Terbinafine reduces Cl caffeine with iv administration by 19%.
In vivo and in vitro studies have shown that terbinafine inhibits the metabolism mediated by the enzyme 2D6 (CYP2D6). These data may turn out to be clinically significant for those drugs that are metabolized primarily by this enzyme: tricyclic antidepressants, beta-blockers, selective serotonin reuptake inhibitors, antiarrhythmic drugs of class (1A, 1B and 1C) and MAO type B inhibitors, if the drug used simultaneously has a small range of therapeutic concentration.
Terbinafine reduces Cl desipramine by 82%.
Terbinafine may attenuate the effects of cyclosporin and decrease its plasma concentration. Terbinafine increases Cl cyclosporine by 15%.
Overdose
Symptoms: There have been reports of several cases of overdose (the accepted dose of the drug was up to 5 g), in which headache, nausea, epigastric pain and dizziness were noted.
Treatment: symptomatic and supportive therapy, measures to eliminate the drug, primarily by prescribing activated carbon and gastric lavage.
Storage Conditions
In a dark place at a temperature not exceeding 30 ° C.
Expiration
5 years
drugstore prescription
lekarstvennaja form
tablets
